| III-68 Alberto Russu Population pharmacokinetic modeling and bioequivalence clinical trial simulations of niraparib plus abiraterone acetate administered as single-agent combination and dual-acting tablets plus prednisone for the treatment of metastatic castration-resistant prostate cancer Thursday 10:15-11:45 |
